Larkberget

Larkberget Equity

The The Equity of Larkberget (LARK.ST) as of Oct 21, 2026 is 55.49 M SEK. In the previous year, The Equity was 71.58 M SEK — a change of -22.47% (lower).

Equity

55.49 MSEK

YoY

-22.47%

Last updated:

In 2025, Larkberget's equity was 55.49 M SEK, a -22.47% increase from the 71.58 M SEK equity in the previous year.

The Larkberget Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
20.46 M SEK
Jan 1, 2019
18.46 M SEK
Jan 1, 2020
71.43 M SEK
Jan 1, 2021
158.28 M SEK
Jan 1, 2022
152.12 M SEK
Jan 1, 2023
116.46 M SEK
Jan 1, 2024
71.58 M SEK
Jan 1, 2025
55.49 M SEK
The Larkberget Equity history
YEAREquityYoY
55.49 MSEK-22.47%
71.58 MSEK-38.54%
116.46 MSEK-23.45%
152.12 MSEK-3.89%
158.28 MSEK+121.58%
71.43 MSEK+286.86%
18.46 MSEK-9.73%
20.46 MSEK+214.11%
6.51 MSEK+59.63%
4.08 MSEK-60.26%
10.27 MSEK+81.20%
5.67 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Larkberget Stock analysis

What does Larkberget do? CombiGene AB specializes in developing treatments for neurological disorders using gene therapy vectors. The company's platform delivers combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. CombiGene focuses on an epilepsy treatment utilizing an adeno-associated virus (AAV) vector carrying transgenes for NPY and its Y2 receptor. The firm targets neurological and psychiatric diseases in humans and animals through its gene therapy approach. CombiGene AB's products are developed for the treatment of epilepsy and other neurological conditions. The company's platform is designed to deliver multiple therapeutic elements simultaneously via gene therapy vectors. The firm's focus on AAV vectors carrying specific transgenes reflects its strategy to address complex neurological disorders with targeted gene-based therapies. The company's target segments include patients with neurological and psychiatric diseases requiring innovative treatment options. CombiGene AB's development pipeline centers on epilepsy treatment using NPY and Y2 receptor transgenes. The firm's approach involves creating therapies that combine multiple biological components to address disease mechanisms more effectively. Larkberget is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Larkberget's Equity

Larkberget's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Larkberget's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Larkberget's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Larkberget's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Larkberget’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Larkberget stock

The Equity of Larkberget is 55.49 M SEK in 2025.

The Equity of Larkberget changed from 71.58 M SEK to 55.49 M SEK, representing a -22.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Larkberget since 2006 – with annual values, charts, and detailed analysis.

The Equity's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Larkberget historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Larkberget

All Key Metrics — Larkberget